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ABSTRACT

PARTICULATE HEXAVALENT CHROMIUM INHIBITS HOMOLOGOUS
RECOMBINATION REPAIR BY TARGETING RAD51 PARALOGS IN HUMAN
LUNG FIBROBLASTS

Aggie R. Williams
March 4, 2022

Hexavalent Chromium [Cr(VI)] is a known human lung carcinogen and general
health hazard. The mechanism of carcinogenesis remains poorly understood, but
chromosome instability (CIN) is the major theory in its carcinogenic mechanism.
Homologous recombination (HR) repair is a DNA repair pathway that prevents
CIN by repairing DNA double-strand breaks. RAD51, a key mediator protein of
HR repair, along with the RAD51 paralogs (RAD51B, C, D, XRCC2, and 3) are
required for HR repair. During HR, RAD51 loads and forms a helical
nucleoprotein filament structure to promote DNA strand exchange and stimulate
pairing activity of DNA. Cr(VI) exposures have been shown to target RAD51 and
prevent its loading in lung fibroblasts. The mechanism by which Cr(VI) impacts
RAD51 paralogs to cause RAD51 dysfunction remains unknown. In this study,
we investigate the effects of Cr(VI) on these paralogs and their complexes in
v

human lung cells. This study found both acute and prolonged Cr(VI) exposure
inhibits RAD51D repair response evidenced by decreased RAD51D foci
formation, protein levels and gene expression. In contrast, Cr(VI) had minimal
effect on XRCC3 repair function, suggesting RAD51D as a part of the BCDX2
complex may be a key initial target in Cr(VI)-induced loss of RAD51 function and
HR repair.
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INTRODUCTION
Carcinogenicity of Chromium
Chromium Exposure
Chromium (Cr) is a metal commonly found in Earth’s crust. Cr’s desirable
properties include its hardness, bright pigmentation, non-corrosive, and nonoxidative properties. Cr is used to build and plate objects to protect them from
oxygen and corrosion. On a larger scale, Cr is used in the metallurgical and
chemical industry to produce stainless steels, alloys, and plating steel, as well as
coloring agents for pigments, paints and dyes, wood preservation, and leather
tanning. Cr’s potential for widespread industrial and commercial use continues to
expand for companies around the globe.

Cr occurs in two environmentally stable valence states: trivalent chromium Cr(III)
and hexavalent chromium Cr(VI). The trivalent form of chromium readily binds to
extracellular molecules and is prevented from entering the cells. Cr(III) was initially
believed to be a nontoxic and essential element for humans due to its effects on
insulin action. Further research indicated that although Cr(III) may have
pharmacological benefits, it is not essential. In 2014, the European Food Safety
Authority Panel on Dietetic Products, Nutrition, and Allergies concluded there is no
evidence suggesting chromium is an essential nutrient and, therefore, setting
chromium intake recommendations would be inappropriate (EFSA, 2014).
1

Cr(VI) is also not essential, but unlike Cr(III), Cr(VI) poses a major level of concern
to human health, particularly because of its ability to induce lung cancer. Cr(VI) is
more toxic than Cr(III) because of uptake. Cr(VI) gets transported easily into the
cell as chromate, which structurally resembles sulfate and phosphate. Thus,
chromate can use the same channels as sulfate and phosphate and enters by the
process of facilitated diffusion. By contrast, Cr(III) binds many available ligands
extracellularly, which makes it too structurally bulky to use these transporters and
it can only enter very slowly by simple diffusion (Figure 1). Once inside the cell,
Cr(VI) gets rapidly reduced to Cr(III) generating Cr(IV), Cr(V) as well as reactive
oxygen species in the process. Although Cr(VI) is toxic, it is not the ultimate
toxicant. The actual species that is the ultimate carcinogen remains unknown with
evidence supporting Cr(III), Cr(V), Cr(IV) and reactive oxygen species or possibly
some combination of them.
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Figure 1: Properties of Chromium
This figure shows the two environmentally stable valence states of chromium that
determine its toxicological effects. Cr(III) does not readily enter the cell because it
binds to extracellular molecules. Cr(VI), however, uses anion transport to readily
enter cells where it is reduced to Cr(III).
Evidence that Cr(VI) Causes Cancer
According to the Occupational Safety and Health Administration (OSHA 2006), all
Cr(VI) compounds are considered carcinogenic to workers and the risk of
developing lung cancer increases with the amount of Cr(VI) inhaled and the length
of individual exposure. The Environmental Protection Agency (EPA 1999)
classifies Cr(VI) as an agent within Group A: a known human carcinogen. Cr(VI) is
listed as 17th most hazardous substance posing significant threat to human health
by the Agency for Toxic Substances and Disease Registry (ATSDR 2012). This
agency prioritizes substances based on toxicity and their potential for human
exposure. All these regulations were conclusions based on epidemiology, animal
and cell culture studies which indicate Cr(VI) compounds, when inhaled, cause
lung cancer in humans. Cr(VI) poses a significant environmental health risk but
despite well- known toxic effects, its carcinogenic mechanism remains poorly
understood.

Epidemiological studies consistently show increased lung cancer rates in workers
exposed to varying levels of Cr(VI) in the air. Pathology studies show the principal
tumor type induced by Cr(VI) are bronchial carcinomas (Langard & Vigander
1983). Kishi et al., (1987) measured exposure to specific amounts of chromium
over a decade in people who worked at a chromate chemical manufacturing plant.
The amount of chromium in the lungs of workers for over 10 years averaged 51.5
3

ug/g (range 24.8-210 ug/g), while Cr levels in the lungs of non-exposed controls
were 0.07-1.01 ug/g. Interestingly, chromate cancers found in the tumors exhibited
molecular features different than those cancers induced by smoking, such as
microsatellite instability and a specific pattern of methylation of tumor suppressor
genes (Urbano et al., 2012). Human pathology studies also reveal both Cr-induced
tumors and Cr accumulation occur at bronchial bifurcation sites (Ishikawa 1994).
In addition, these studies show Cr(VI) persists in the lungs years after exposures
have ceased. For example, a follow up study done by Mancuso & Hueper (1951)
conducted on 332 chromate workers employed from 1931 to 1951 in Painesville,
OH, showed 50% of mortality by 1974. Of the 50% of the men that died, 63.6%,
62.5% and 58.3% of cancer deaths for the ones employed in 1931-1932, 19331934 and 1935-1937 were due to lung cancer. The lungs measured from
employees showed lung cancer death rates increased with increased exposure,
and the deposition of chromium found in the lungs of workers were long after
exposure ceased.

Cr(VI) compounds cause tumors in experimental animals. For example, Levy et
al., 1986 used intrabronchial pellet implantation of several species of hexavalent
chromates in rat lungs that produced bronchial carcinomas. Another study done
by Farris (2014) showed Cr(VI) compounds administered long-term by inhalation
were found to produce lung tumors. These whole animal studies confirm
epidemiological studies and establish that Cr(VI) can cause tumors. Thus,
Cr(VI)induced animal and human tumors have been further investigated in cell
culture studies to confirm Cr(VI) compounds are carcinogenic with respect to lung
4

cancer. The results of these studies support the classification of Cr(VI) compounds
as carcinogens.

Cell culture studies were also used to confirm the carcinogenicity of Cr(VI)
compounds showing they induced neoplastic transformation (Xie et al., 2007). For
example, Wise et al, investigated neoplastic transformation caused by Cr(VI)
exposure in clonal cell lines using an anchorage independent assay to detect
transformation of cultured cells (Wise et al., 2018). The ability for cells to grow in
soft agar is a property acquired by neoplastic cells. Data showed 14.4% of firstgeneration clones grew in agar, 12.5% of second-generation clones grew in agar,
and 20.5% of third generation clones grew in soft agar. None of the control clones
grew in agar.

Role of Solubility in Cr(VI) Carcinogenesis
Another key factor of Cr(VI) carcinogenicity is water solubility. While all Cr(VI)
compounds are classified as carcinogens, not all Cr(VI) compounds have
equivalent carcinogenic potencies. Cr(VI) compounds can either be water soluble
(i.e., sodium and potassium chromates) or water insoluble (i.e., lead and zinc
chromates). Numerous available data from epidemiological, animal, and cell
culture studies show water insoluble (particulate) salts are more potent than water
soluble ones (Holmes et al., 2008). Zinc chromate for example, a water insoluble
'particulate' Cr(VI) compound was shown to be carcinogenic in epidemiology
studies and to cause tumors in experimental animals. The underlying explanation
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for why the particulates are more potent comes from pathology studies, which
show increased levels of Cr levels and tumor formation at lung bifurcation sites
where particles are expected to impact and persist, and from culture data that show
the particle-cell contact leads to extracellular dissolution in the immediate
microenvironment of the cell indicating the particles can act like a localized Cr(VI)
sink, while soluble compounds are more readily cleared.

Mechanism of Cr(VI) Carcinogenesis
The mechanism of carcinogenesis by Cr(VI) remains poorly understood. However,
the dominant theory is that Cr(VI) drives the formation of lung tumors by inducing
chromosome instability, including structural and numerical alterations in the
chromosomes (Hirose et al., 2002). Structural chromosome instability results from
Cr(VI) inducing DNA double strand breaks that, when unrepaired, progress to
structural chromosomal changes. Notably, Cr(VI) also inhibits DNA double strand
break repair (Qin et al., 2014). How, this inhibition occurs is poorly understood and
is the focus of this thesis.

Cr(VI)-induced DNA Double Strand Breaks
Cell culture studies show Cr(VI) causes DNA double strand breaks after acute and
prolonged exposures (Holmes et al., 2008; Wise and Wise 2012; Wise et al., 2008;
Xie et al., 2008). DNA double strand breaks were measured by gamma H2AX foci
formation or with single gel electrophoresis assay (neutral comet assay). The
breaks formed in the late S and G2 phases of the cell cycle (Ha et al., 2004; Xie et
al., 2005). The cause of the double strand breaks likely involve several factors.
6

Some breaks forms as a result of crosslinks/ternary adducts from either their repair
by excision repair or from the collapse of stalled replication forks. Breaks can also
form from an unrepaired single strand break entering S or G2 and being converted
to a DNA double strand break or from futile mismatch repair (Holmes et al., 2004,
Wise et al., 2008).

Cr(VI) Targets RAD51 to Inhibit DNA Double Strand Break Repair
When a DNA double strand break occurs, the break is recognized and primarily
repaired by one or the other of two different pathways: homologous recombination
(HR) and non-homologous end joining repair (NHEJ). Of these two, HR is the
pathway that protects against Cr(VI) carcinogenesis and chromosome instability.
(Stackpole et al., 2007)

Cr(VI) inhibits HR repair, allowing unrepaired breaks to cause chromosome
instability (Figure 2). Browning et al. 2016 observed cells after prolonged exposure
to Cr(VI) (>72 h) and found reduced HR repair (Browning et al., 2016). HR
signaling and repair involves several steps, including sensing the damage
(sensor), transducing, and amplifying the repair signal (transducer), resection, and
carrying out the repair (effector). Several

proteins, including H2A.X, MRE11,

RAD50, NBS1, ATM and RAD51, among others play significant roles in HR. After
a break occurs, the initial processing involves the MRN (MRE11, RAD50, NBS1)
complex as a part of the sensing step. ATM is recruited during the transducing step
to signal proteins downstream for repair. RAD51 is the signature downstream
effector protein in HR. Qin et al (2014) found proteins early in the HR signaling
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pathway responded normally after Cr(VI) exposure. In contrast, they found the later
effector steps were altered by Cr(VI), specifically altering RAD51. In particular, the
data show inhibition of RAD51 foci formation, protein levels, and nucleoprotein
filament formation after prolonged exposure (Qin et al., 2014; Browning et al.,
2016) . However, how Cr(VI) alters RAD51 function is unknown.

Figure 2: Particulate Cr(VI) Physico-chemical-biological Mechanism in

human cells
This figure shows Cr(VI) induces DNA double strand breaks while simultaneously
inhibiting the repair of those breaks, which results in CIN, neoplastic transformation
and ultimately cancer.
RAD51 Paralogs as Possible Targets to Explain the Loss of RAD51 Function
RAD51 initiates single strand invasion and homology pairing in sister chromatids
during the effector stage of HR (Sung and Robberson., 1995). The key function of
RAD51 is to form a helical nucleoprotein filament which promotes repair activities.
However, prolonged exposure to particulate Cr(VI) inhibits the formation of this
RAD51 filament (Browning et al., 2016). Loss of this filament is thought to be a key
event in Cr(VI) carcinogenesis resulting in loss of HR repair and allowing the
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unrepaired breaks to destabilize the chromosomes. However, how Cr(VI) induces
the loss of this filament is unknown.

There are several proteins involved in forming the RAD51 nucleofilament. These
proteins are referred to as RAD51 paralogs because they share 20-30% amino
acid sequence identity with RAD51 (Thacker 1999). They are thought to originate
from a gene duplication of the ancestral RADA protein and have maintained their
structural resemblance to RAD51. The five classical RAD51 paralogs are RAD51B,
RAD51C, RAD51D, XRCC2 and XRCC3. Each is an important component of the
HR pathway. In the early stages of HR, the paralogs act by regulating either the
assembly or stability of the RAD51 nucleoprotein filaments. Deficiency in any of
these paralogs results in chromosomal abnormalities, decreased DNA damageinduced sister chromatid exchanges, reduced RAD51 focus formation, and
deficiency in replication fork protection (Garcin et al., 2019)

The paralogs exist in two distinct complexes: the BCDX2 complex (RAD51BRAD51C-RAD51D-XRCC2) and the CX3 complex (RAD51C-XRCC3) (Masson et
al., 2001) (Figure 3). These two complexes act during different stages of the HR
pathway. The BCDX2 complex acts during RAD51 recruitment (Yonetani et al.,
2005; Chun et al., 2013) and plays a role in RAD51 filament formation and
stabilization. By contrast, the CX3 complex acts downstream of RAD51
recruitment. promoting RAD51 nucleofilament remodeling, stability, and strand
invasion.
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How Cr(VI) affects the paralogs, and these complexes is poorly understood. The
only available data show Cr(VI) can inhibit RAD51C foci formation after prolonged
exposures, but had no effect on RAD51C whole cell protein levels (Browning et
al., 2016, Browning et al., 2018). No studies so far have investigated the effect of
Cr(VI) on the remaining paralogs. Therefore, this study focuses on the effects of
Cr(VI) on two additional RAD51 paralogs RAD51D and XRCC3, representing the
BCDX2 and CX3 complexes, respectively .

Figure 3: Schematic of Canonical RAD51 paralog Complexes This figure
shows the steps of DSB repair through HR and complexes BCDX2 (consisting of
RAD51B, RAD51C, RAD51D, and XRCC2) and CX3 (consisting of RAD51C and
XRCC3).
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MATERIALS & METHODS

Chemicals and reagents
Cell Culture
WTHBF-6 cells, an hTERT immortalized clonal cell line derived from human
bronchial fibroblasts, were used as a representative human lung cell line. The
bronchial cell strain, isolated from normal lung of a 67-year-old Caucasian male
and this cell line exhibits normal growth parameters and a normal stable karyotype.
WTHBF-6 cells were maintained as a monolayer in Dulbecco’s Modified Eagle
Medium/Nutrient Mixture F- 12 (DMEM/F- 12) supplemented with 15% Cosmic calf
serum (CCS), 1% Corning glutaGRO supplement, 0.1 mM sodium pyruvate, and
1% penicillin/streptomycin and fed every other day. Cells were sub-cultured every
three to four days using 0.25% trypsin-EDTA. All experiments were maintained in
a 37°C, humidified incubator with 5% CO2.
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Chromium Preparation

Suspensions of zinc chromate particles were prepared by rinsing twice in doubledistilled water to remove any water-soluble contaminants. Then the particles
were washed twice in acetone to remove any organic contaminants. The washed
particles were air-dried, weighed, and placed in double-distilled water in a
borosilicate scintillation vial and stirred overnight with a magnetic stir bar at 4°C.

In previous studies by the Wise Laboratory these methods were shown to result in
particles in the size range of 0.2-2.3 um with a mean size of 2.7 um. During the
preparation of the appropriate dilutions and during the treatment procedure the
particles were kept in suspension using a vortex mixer. Final chromate
concentrations in cell culture ranged from 0-0.3 ug/cm2 for the zinc chromate
treatments. The dilutions were dispensed directly into cultures from these
suspensions which are environmentally relevant ranges to which humans may be
exposed.

Cell Treatments

For all experiments, cells were seeded and allowed 48 h to enter logarithmic
growth before treatment. Before treatment, the medium was changed and the zinc

12

chromate suspension was added at a concentration of 0, 0.1, 0.2, or 0.3 ug/cm 2 to
fresh media unless otherwise specified. Treatment durations were for 24 or 120 h.

Immunofluorescence Assay

For the immunofluorescence assay, cells were seeded on four well glass slides,
fibronectin (FNC) coating mix-coated chamber slides. For the 24 h treatment
conditions (0, 0.1, 0.2 and 0.3 ug/cm 2), 12,000 cells were seeded in each well of
the four well glass. For 120 h 0-0.3ug/cm2 were seeded with 3000 cells whereas
0.2 ug/cm2 wells were treated with 4000 cells and 6000 for 0.3 ug/cm2. Cells were
allowed 48 h to enter logarithmic growth before treatment with zinc chromate. At
harvest, after
24 or 120 h exposure, media was aspirated, and cells were rinsed with Dulbecco’s
phosphate-buffered saline (DPBS).

For RAD51D foci, cells were fixed with 4% paraformaldehyde for 5 min,
permeabilized with 0.2% Triton X-100 for 5 min and blocked with 10% goat serum
and 5% Bovine serum albumin (BSA) in Phosphate buffer saline (PBS) for 30 min.
Cells were then incubated with anti-RAD51D (NB100-178; 1:500) antibody for 1 h,
washed with PBS and incubated with Alexa Fluor 488 goat anti-mouse igG
(2066710; 1:1500) for 1 h in the dark. For XRCC3 foci, cells were fixed with 100%
methanol at -20°C for 5 min and blocked with PBS containing 4% BSA at 4°C
overnight, Cells were then incubated with XRCC3 (NB100-10F1/6; 1: 500)
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antibody for 1 h at 37°C in a humid environment using a slide warmer. washed with
PBS and incubated with Alexa Fluor 488 goat anti-mouse igG (2066710; 1:1000)
for 1 h at 37°C in a humid environment using slide warmer in the dark. Cells were
washed with PBS and coverslips were mounted with a simple fluorescent stain,
4',6-diamidino-2-phenylindole (DAPI).

Nuclear foci were scored in 100 cells per concentration/timepoint using
fluorescence microscopy. Results were expressed as the percentage of cells with
>20, >5 or >11 foci based on background levels such that negative controls had
5% or less of cells with this level. Images of cells per concentration/timepoint were
obtained with an Olympus confocal microscope.

Western Blot Assay

Cells were seeded on 100 mm dishes and allowed 48 h to enter logarithmic growth
phase. Cells were treated as described above. At the end of the treatment period,
after 24 h or 120 h, media was removed, and cells were rinsed with PBS and
released from the plate with 0.25% trypsin-EDTA. Cell pellet were collected in 1.5
ml microfuge tubes. Whole cell extracts were obtained by washing, collecting and
incubating cells in 500 μl of extraction buffer (Pierce RIPA Buffer (Thermo 89900))
with protease and phosphatase inhibitors 100x (Thermo 78440) for 20 min on ice.
Cells were centrifuged at 14 000 rpm for 10 min. Supernatant was collected and
stored at −80 °C. Immunoblots were probed with anti-Rad51 (Santa Cruz sc38819; 1:1000) or anti-RAD51D (Santa Cruz SC-38819; 1:1000). Equal loading
14

was confirmed by Alpha-tubulin (Cell Signaling 11H10; 1:1000). Nuclear protein
extract was resolved on either 12% Bis-Tris SDS-PAGE gels or precast gel for use
with tris/glycine buffers and transferred to either PVDF membranes or
nitrocellulose membranes. Immunoblots were incubated with Alexa680 or
Alexa800 (1:3000, 1:15000) secondary antibodies and fluorescence detected
using an Odyssey Imager (LiCor, Lincoln, Nebraska).

Quantitative reverse transcription PCR (RT-qPCR)

Cells were seeded on 100 mm dishes and allowed 48 h to enter logarithmic growth
phase. Cells were treated as described above. At the end of the treatment period,
after 24 or 120 h, media was removed, and cells were rinsed with PBS and
released from the plate with 0.25% trypsin-EDTA. Cell pellet were collected in 1.5
ml microfuge tubes. Total RNA extracts were obtained, and cDNA was prepared
using a mirVana miRNA isolation kit, with phenol, Thermo Fisher; (AM1560) and
TaqMan assay probes using manufacturer’s instructions. Briefly, cells were lysed
directly in the culture plates and homogenized. RNA was extracted using acidphenol chloroform and the aqueous phase was transferred to filter cartridges. Total
RNA was washed several times using ethanol and eluted into a fresh tube. RNA
quality and concentration were measured using a Nanodrop ND-1000
spectrophotometer. cDNA synthesis was carried out using a High-Capacity cDNA
Reverse Transcription Kit per the manufacturer’s instructions with slight
modifications. Briefly, 2 RT master mix was prepared using random primers,
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combined with 2 lg total RNA (per 20ul reaction). TaqMan RNA primers (
Hs00864094_m1;

RAD51D-

Hs00979562_m1;

GAPDH-Hs027899_)

were

combined with TaqMan Universal PCR Master mix II (Thermo Fisher Inc ) and
cDNA in triplicate. The no RNA and no reverse transcriptase controls from cDNA
synthesis and a no cDNA control were included in all qPCR runs. Protocols were
utilized designed to use with STepOne Plus quantitative polymerase chain reaction
(qPCR) machine. The CT threshold was set by instrument’s calculations and
results are displayed as CT values relative to the untreated (0 ug/cm 2 zinc
chromate) control for each time point, respectively.

Statistical Analysis

Student’s t-test were conducted to determine statistical significance between data
points. ANOVA was also used for comparisons between timepoints. Results were
expressed as the mean ± SEM (standard error of the mean) of 3 independent
experiments. Statistical significance was determined to be a p value less than 0.05.
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RESULTS
Particulate Cr(VI) Inhibits RAD51D Foci Formation
We focused on RAD51D as a representative of the BCDX2 complex. We evaluated
the ability of Cr(VI) to inhibit the function of RAD51D through foci formation using
immunofluorescence (Figure 4A). Particulate Cr(VI) inhibited RAD51D foci
formation in a concentration dependent manner after 24 and 120 h exposure
(Figure 4B). Specifically, 0.2, and 0.3 ug/cm2 zinc chromate reduced the percent
of cells with more than 11 RAD51D foci to 3.9, and 2.4 percent, respectively
compared to 5.8 percent in untreated controls. A somewhat greater inhibition was
seen after a 120 h exposure as 0.1, 0.2, and 0.3 ug/cm 2 zinc chromate reduced
the levels to 6.3, 3.3, and 2.3 percent, respectively, compared to 7.4 percent in
untreated controls. At both time points, both 0.2, and 0.3 ug/cm 2 were significantly
lower than their respective controls (P<0.05).
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A.

B.

Figure 4. Particulate Cr(VI) Inhibits RAD51D Foci Formation.
This figure shows acute and prolonged zinc chromate exposure reduced
RAD51D foci formation in a time and concentration-dependent manner. (A)
representative immunofluorescence images of RAD51D foci. (B) Quantification of
the percent of cells with RAD51D foci. Data represent the mean of three
experiments. Error bars = standard error of the mean. *Statistically significant
compared to control p< 0.05.
18

Particulate Cr(VI) Inhibits RAD51D Whole Cell Protein
To determine if the lack of RAD51D foci was due to a decrease in protein
expression, whole cell RAD51D protein was measured by western blot (Figure 5A).
Particulate Cr(VI) reduced whole cell RAD51D protein levels in a concentrationdependent manner after 24 and 120 h exposure (Figure 5B). After 24 h exposure,
RAD51D protein levels decreased at 0.2, and 0.3 ug/cm2 zinc chromate to 83 and
76% of control. An even greater reduction was seen after 120 h exposure as 0.1,
0.2, and 0.3 ug/cm2 zinc chromate reduced protein levels to 60, 56 and 43%,
respectively. At both time points, 0.2, and 0.3 ug/cm 2 were significantly lower than
their respective controls (P<0.05).

A.
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B.

Figure 5. Particulate Cr(VI) Inhibits RAD51D Whole Cell Protein
This figure shows acute and prolonged zinc chromate exposure reduces RAD51D
protein levels in a time and concentration-dependent manner. (A) representative western
blot images of whole cell RAD51D protein expression (cropped from original image). (B)
Quantification of RAD51D whole cell protein (relative to control). Data represent the
mean of three experiments Error bars = standard error of the mean, *statistically
significant compared to control p< 0.05.

Particulate Cr(VI) Inhibits RAD51D mRNA Levels.
We tested if Cr(VI) inhibits RAD51D mRNA levels using quantitative polymerase
chain reaction (qPCR) following particulate Cr(VI) exposure. Particulate Cr(VI)
inhibited RAD51D mRNA levels in a concentration-dependent manner after 24
and 120 h exposure (Figure 6). After 24 h, RAD51D mRNA was reduced to 0.66,
0.51, and 0.43 relative to control following 0.1, 0.2, and 0.3 ug/cm 2 zinc
chromate. RAD51D mRNA remained low after 120 h decreasing to 0.54, 0.27,
and 0.24 relative to control. After prolonged exposure of 120 h RAD51D mRNA
was significantly reduced at all concentrations compared to control
(P<0.05).
20

Figure 6. Particulate Cr(VI) Inhibits RAD51D mRNA Levels.
This figure shows acute and prolonged zinc chromate exposure reduces RAD51D
mRNA levels in a time and concentration-dependent manner. Data represent the mean
of three experiments Error bars = standard error of the mean, *statistically significant
compared to control p< 0.05. Quantification of RAD51D whole cell protein (relative to
control).

Particulate Cr(VI) Slightly Inhibits XRCC3 Foci Formation
We focused on XRCC3 as a representative of the CX3 complex. We evaluated the
ability of Cr(VI) to inhibit the function of XRCC3 through foci formation using
immunofluorescence (Figure 7A). Particulate Cr(VI) did not affect XRCC3 foci
formation after 24 h exposure (2.9, 2.8, 2.6 percent) but slightly inhibited XRCC3
foci formation in a concentration-dependent manner after 120 h exposure (Figure
7B). Specifically, 0.2, and 0.3 ug/cm2 zinc chromate reduced the percent of cells
with more than 5 XRCC3 foci to 2.2, and 1.6 percent, respectively, compared to
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2.8 percent in untreated controls. Although these small reductions were not
statistically significant compared to control.

A.

B.

Figure 7. Particulate Cr(VI) Slightly Inhibits XRCC3 Foci Formation
22

This figure shows prolonged zinc chromate exposure slightly reduces XRCC3 foci
formation in a concentration-dependent manner. A) representative immunofluorescence
images of XRCC3 foci. (B) Quantification of the percent of cells with XRCC3 foci. Data
represent the mean of three experiments Error bars = standard error of the mean.
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DISCUSSION
Particulate hexavalent chromium Cr(VI), a human lung carcinogen, is an
environmental contaminant that poses harm to human health; however, the
mechanism of Cr(VI) carcinogenesis remains poorly understood. Cr(VI) induces
chromosome instability, a hallmark event in lung cancer. The formation of DNA
double strand breaks combined with DNA double strand break repair failure are
major underlying events that lead to chromosome instability.

Previous studies show homologous recombination repair is the preferred
mechanism for repairing Cr(VI) induced double strand breaks in DNA double
strand breaks (Bryant et al., 2006; Stackpole el al., 2007; Xie et al., 2009; Tamblyn
et al., 2009). Notably, particulate Cr(VI) causes DNA double strand breaks and
prolonged exposure impairs homologous recombination by targeting the key
protein, RAD51, in the effector step of this pathway (Qin et al., 2014). During
homologous recombination, RAD51 is loaded onto single-stranded DNA, creating
a helical nucleoprotein filament responsible for carrying out repair. Data show
prolonged exposure to particulate Cr(VI) prevents RAD51 nucleofilament
formation (Browning et al., 2016), however, how it causes the loss of this filament
is poorly understood.
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Because of the observations of loss of RAD51 nucleofilament formation, the first
goal of this study investigated how Cr(VI) targets key complexes in homologous
recombination repair critically important for the loading and stability of RAD51 onto
the filament in human lung cells. We focused on RAD51D, because its depletion
would represent a loss of function in the BCDX2 complex, which is the central
mediator of RAD51 loading (Chun et al. 2013). We showed RAD51D foci formation
decreased following both acute and prolonged particulate Cr(VI) exposure
indicating a loss of function as early as 24 h after exposure. This finding is notable
because RAD51 functions appropriately to 24 h Cr(VI) exposure, evidenced by an
increase in the number and complexity of RAD51 nucleoprotein filaments
(Browning et al., 2016). This outcome suggests there is sufficient RAD51 loaded
onto the filament after 24 h, which agrees with the previous report of increased
RAD51 foci formation following acute Cr(VI) exposure (Browning et al., 2016, Qin
et al., 2014). Both RAD51D and RAD51 are suppressed after 120 h of exposure
indicating the outcome worsens with longer exposure. RAD51D is responsible for
the formation and stabilization of RAD51 nucleofilament formation. This protein is
also involved in protecting the integrity of sequences during double strand breaks,
and specifically protects against large deletion events. RAD51D stabilizes the
RAD51 nucleoprotein filament upstream of its formation (Chun et al., 2013).
Therefore, the observed inhibition of RAD51D’s response suggests the defects in
RAD51 nucleofilament formation results from Cr(VI) targeting RAD51D.

Only one other study showed Cr(VI)-induced inhibition of HR repair looking at
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RAD51 paralogs in the BCDX2 complex. That study focused on RAD51C and
found Cr(VI) exposure did not inhibit RAD51C after 24 h exposure as RAD51C foci
increased in a concentration dependent manner after 24 h just as RAD51 did
(Browning et al. 2016). However, with longer exposures RAD51C was also
inhibited and suppressed. These data, when combined with the data in this study,
suggest that RAD51D is targeted first followed by RAD51C with longer exposures.
The loss of both proteins may exacerbate the RAD51 loss on the filament as data
showed double depletion of components in the BCDX2 complex lead to additional
loss of RAD51 foci formation (Chun et al., 2013). The BCDX2 complex has been
reported to form subcomplexes (BC and DX2) (Sigurdsson et a1., 2001). Data
indicate the DX2 subcomplex may have a greater role than the BC subcomplex in
RAD51 filament stabilization (Chun et al., 2013), which would be consistent with
our results showing RAD51D as the primary target.

How Cr(VI) impairs RAD51D is uncertain. We showed RAD51D protein expression
decreases following both acute and prolonged exposures. The decrease in
RAD51D protein levels could be a result from either decreased protein production
or protein degradation. However, we also found RAD51D mRNA expression
decreased following both exposures, which suggests loss of protein synthesis is
the likely explanation.

The second goal of this study was to investigate XRCC3 as a representative of the
CX3 complex in human lung cells, which functions downstream of RAD51
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recruitment. We focused on XRCC3, because its depletion or deletion would
represent a loss of function in the CX3 complex (Chun et al. 2013). Our
understanding of the interaction between RAD51C and XRCC3 is limited due to
very few studies reported. One genetic study looking at CX3 complex in treated
DT40 cells confirmed RAD51C/XRCC3 functions at later stages of replication
dependent repair induced by camptothecin and cisplatin (Yonetani et al., 2005).
Another study showed the CX3 catalyzes strand exchange in vitro suggesting this
complex may be important for the catalysis of homologous pairing between
homologous chromosomes during recombination repair (Kurumizaka et al., 2001).
We found no significant effects on XRCC3 following Cr(VI) exposure suggesting
this protein is not a major target for Cr(VI). However, RAD51C is part of the CX3
and data show RAD51C depletion has a more pronounced effect on the CX3
complex than on the BCDX2 complex in U2OS cells (Chun et al., 2013). Thus,
considering the results previously reported (Chun et al., 2013), it is likely the CX3
complex is targeted by Cr(VI) due to Rad51C loss, which would impact the repair
of any cells that escape the loss of the BCDX2 complex.
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SUMMARY AND CONCLUSIONS

Strengths of this work
This work is pioneering in that currently there are no data investigating the
effects of Cr(VI) on RAD51 paralog complexes. This is the first study to evaluate
RAD51 paralogs function after Cr(VI) exposure in human cells. The primary
target of particulate Cr(VI) exposure is the lung. We evaluated how particulate
Cr(VI) altered RAD51 paralogs in human lung cells after acute and prolonged
Cr(VI) exposures.

Future Directions
This work requires more mechanistic data to gain better understanding of how
Cr(VI) affects RAD51 and its paralogs in humans. More mechanistic data
investigating how Cr(VI) exposure affects other members of the BCDX2 complex
and consequences of impaired RAD51D will be further investigated. Future work
will consider the impact of Cr(VI) on other members of the RAD51 paralog
complexes and the mechanism of Cr(VI)- induced BCDX2 inhibition of
homologous recombination repair in metal carcinogenesis.
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Conclusions
Overall, our data modify the mechanism for Cr(VI) carcinogenesis to show first
Cr(VI) targets RAD51D resulting in loss of RAD51 leading to reduced
homologous recombination repair response resulting in chromosome instability
and ultimately carcinogenesis.
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